Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Colorectal Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Metastatic Colorectal Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Metastatic Colorectal Cancer

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Recurrent Head And...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Oral Cavity (Mouth) Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Oral Cavity (Mouth)...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Oral Cavity (Mouth) Cancer

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Oropharyngeal Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Oropharyngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Oropharyngeal Cancer

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Laryngeal Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Laryngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Laryngeal Cancer

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Hypopharyngeal Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Hypopharyngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Hypopharyngeal Cancer

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Hepatocellular Carcinoma: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Hepatocellular Carcinoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Hepatocellular Carcinoma

Data Insights

TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval

TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Nasopharyngeal Cancer